Synthelabo's device sales up 11% in first half:
This article was originally published in Clinica
Executive Summary
Synthelabo's medical device sales rose 11.4% to Fr 389 million ($76 million) in the first six months of 1996 compared with the previous year. Ela Medical achieved sales of Fr 288 million, an increase of 12.8% over the first half of 1995. Sales at Porges, Synthelabo's catheter division, were Fr 101 million, an increase of 7.4% on a comparable basis. Synthelabo group sales rose 10.9% in the first half of 1996 to Fr 5,122.6 million and the company says 1996 year sales should top Fr 10,000 million.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.